Page 2 - Mark Oki News Today

Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results ...

Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing ...

Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference ...

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q4 2023 Earnings Call Transcript September 27, 2023 Operator: Greetings. Welcome to the Aytu BioPharma Fiscal 2023 Q4 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note this conference is being recorded. I will now […]

27.09.2023 - Q4 2023 net revenue of $30.7 million; Adjusted EBITDA of $7.7 millionRecord Q4 2023 total prescriptions increased 32% compared to Q4 2022Rx Segment net revenue of $23.3 million and Adjusted EBITDA of $8.3 million in Q4 2023Company to host conference ...

Aytu BioPharma to Report Fourth Quarter and Fiscal 2023 Financial Results ...

Abhinav Jain of Nantahala Capital Management, LLC Joins the Company's Board of Directors Upon ClosingPotential for Additional $7 Million in Event of Exercise of Common Warrants in FullExtends Interest

Operator: Greetings. Welcome to the Aytu BioPharma Fiscal 2023 Q3 Results Conference Call. At this time, all participants are in a listen-only mode.

ENGLEWOOD, CO / ACCESSWIRE / May 4, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription

Aytu BioPharma to Report Third Quarter Fiscal 2023 Financial Results ...